Key facts
- This page summarizes Ashley McEvoy's Form 4 filing for JOHNSON & JOHNSON (JNJ).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Aug 2023, 16:07.
Ashley McEvoy - 23 Aug 2023 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)
- Reporting relationship
- EVP, WW Chair, MedTech
- Issuer ticker
- JNJ
- Reported as of
- 23 Aug 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Aug 2023, 16:07:43 UTC
- Prior SEC filing
- 15 Feb 2023
- Next SEC filing
- 14 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Raavi K. Deol, as attorney-in-fact for Ashley McEvoy
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ashley McEvoy filed Form 4 for JOHNSON & JOHNSON (JNJ) on 25 Aug 2023.
Change
- Previous filing in this sequence was filed on 15 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JNJ
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $0
- Shares
- -2,787
- Change %
- -5.1%
- Price
- $0.000000
- Shares after
- 52,038
- Date
- 23 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
JNJ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,806
- Date
- 23 Aug 2023
- Ownership
- By 401k
- Footnotes
- F3
JNJ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 300
- Date
- 23 Aug 2023
- Ownership
- By ESOP
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Compensation & Benefits Committee of the Board of Directors of Johnson & Johnson approved the disposition of these shares of Johnson & Johnson common stock.
Footnote F2
On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer.
Footnote F3
Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023).
Footnote F4
Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023).